In addition, expression of SPTBN2 correlates with the proportion of immune and stromal cells in each tumor, suggesting that SPTBN2 levels are closely correlated with immune activation in a variety of tumors such as PAAD (Fig. 5b, p < 0.05). This evidence concerns the gene SPTBN2 and pancreatic adenocarcinoma.